Literature DB >> 8507873

Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells.

H Hata1, H Xiao, M T Petrucci, J Woodliff, R Chang, J Epstein.   

Abstract

Interleukin-6 (IL-6) has been suggested to play a major role in multiple myeloma. To investigate the source and target cells of IL-6 activity in multiple myeloma, expression of the cytokine and its receptor genes by myeloma plasma cells was studied. Tumor cells were sorted from bone marrow aspirates of myeloma patients using 4-parameter gating. Myeloma cells were identified as CD38high CD45negative-intermediate and by their light-scatter characteristics. Sorted cells contained only myeloma plasma cells. No contaminating cells were present as determined morphologically, by monoclonal cytoplasmic Ig analysis, and by polymerase chain reaction (PCR) amplification of marker genes. Myeloma cells from 45% of patients expressed IL-6. IL-6 receptor transcripts were found in 68% of the specimens. IL-6 gene expression correlated with expression of the IL-6 receptor gene (P < .005). Correlations observed between the expression of CD45, a protein tyrosine phosphatase expressed by B lymphocytes but not by plasma cells, and the expression of the IL-6 and IL-6-receptor genes (P < .0002 and P < .005, respectively) suggest that an autocrine IL-6 loop is functioning in myeloma in preplasma cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8507873

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

1.  An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.

Authors:  Owen W Stephens; Qing Zhang; Pingping Qu; Yiming Zhou; Shweta Chavan; Erming Tian; David R Williams; Joshua Epstein; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

Review 2.  IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation.

Authors:  B E Barton
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  Effect of nutrient starvation on proliferation and cytokine secretion of peripheral blood lymphocytes.

Authors:  Yoshiko Ota; Soichiro Ishihara; Kensuke Otani; Koji Yasuda; Takeshi Nishikawa; Toshiaki Tanaka; Junichiro Tanaka; Tomomichi Kiyomatsu; Kazushige Kawai; Keisuke Hata; Hiroaki Nozawa; Shinsuke Kazama; Hironori Yamaguchi; Eiji Sunami; Joji Kitayama; Toshiaki Watanabe
Journal:  Mol Clin Oncol       Date:  2016-02-03

Review 4.  Myelomagenesis: capturing early microenvironment changes.

Authors:  Neha Korde; Irina Maric
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

Review 5.  Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.

Authors:  D R Lucey; M Clerici; G M Shearer
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

6.  Establishment of a monoclonal antibody to plasma cells: a comparison with CD38 and PCA-1.

Authors:  H Hata; H Matsuzaki; F Matsuno; T Sonoki; S Takemoto; N Kuribayashi; A Nagasaki; K Takatsuki
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

Review 7.  The immune system in the pathogenesis of ovarian cancer.

Authors:  Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

8.  Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells.

Authors:  M A Frassanito; F Silvestris; N Silvestris; P Cafforio; G Camarda; G Iodice; F Dammacco
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

9.  The protein tyrosine phosphatase CD45 is required for interleukin 6 signaling in U266 myeloma cells.

Authors:  Qun Zhou; Yuan Yao; Solveig G Ericson
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490

10.  Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.

Authors:  Karène Mahtouk; Jérôme Moreaux; Dirk Hose; Thierry Rème; Tobias Meissner; Michel Jourdan; Jean François Rossi; Steven T Pals; Hartmut Goldschmidt; Bernard Klein
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.